PDF
Photocure ASA - Share option grant to new CFO
2026-10-27 15:57:34
Oslo, Norway, 27 October 2026 - Photocure ASA (OSE: PHO) has issued 200,000
share options to its new Chief Financial Officer, Mr. Dennis Camporeale at an
exercise price of NOK 54.98 per share. The exercise price is equal to the
weighted average share price 30 trading days before day of grant with an
additional premium of 10% on top of the calculated average price.
The options are granted in accordance with Photocure's long term incentive
program and the company's guidelines for remuneration of senior executives, as
approved by Photocure's annual general meeting held 26 June 2026. The share
option program and properties of the options are further described in the
guidelines.
Primary insider notifications pursuant to the market abuse regulation article 19
are attached.
For more information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com
Priyam Shah
Vice President Investor Relations
Tel: +17176815072
Email: priyam.shah@photocure.com
About Photocure AS
Photocure is a commercial diagnostic company with global reach, committed to
driving progress in uro-oncology precision diagnostics, delivering meaningful
advances for patients with urological cancers. Our unique core technology has
led to better health outcomes for patients worldwide. The company aims to
provide an array of transformative solutions that help physicians with timely
diagnostic information, to inform more personalized decisions on how best to
manage each individual patient. Photocure is headquartered in Oslo, Norway and
listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit
www.photocure.com/news
This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.
19 and 5-12 of the Norwegian Securities Trading\
Act.\